



Common Medicinal Plants and their Role against COVID-19 for Protection and Treatment

Achsha Babu¹, M. Indiraleka², M. K. Mohan Maruga Raja³ and D. Premnath^{1*}

¹Department of Biotechnology, School of Agriculture and Biosciences, Karunya Institute of Technology and Science (Deemed to be University), Coimbatore – 641114, Tamil Nadu, India; prems.bioinfo@gmail.com

²Department of Biotechnology, Mepco Schlenk Engineering College, Sivakasi – 626005, Tamil Nadu, India

³Department of Pharmacognosy and Phytochemistry, Parul Institute of Pharmacy & Research, Parul University, Limda, Waghodia – 391760, Vadodara, Gujarat, India

Abstract

COVID-19 is a deadly serious infectious disease caused by SARS-CoV-2, spreading widely with a rise in number of deaths every day. Because of the rapid transmission, various research domains have much responsibility to find a suitable drug or vaccine as soon as possible within a short time to save lives. Plant based chemical constituents serve as potential therapeutics against COVID-19, which is evident by current reports of screening phytochemicals against potential targets by computational techniques. Medicinal plants are used since ancient times and are known highly for their effective treatment of several infectious diseases. This review summarizes the use of medicinal plants to treat COVID-19 infection and aims to draw more attention towards investigating potent chemical constituents from medicinal plants.

Keywords: Antiviral, Phytochemicals, Secondary Metabolites, SARS-CoV-2

1. Introduction

As of 3rd December 2020, with over 64.5 million confirmed cases and 1.49 million deaths worldwide, the outburst of highly transmissible virus known as Coronavirus (COVID-19) has spread tremendously. The first viral infection was identified in October 2019 at Wuhan city, China. The primary symptoms identified were dry cough, sore throat, fever and shortness of breath and it was confirmed as Corona virus-2 (SARS-CoV-2).

SARS-CoV-2 belongs to the beta genus of Coronaviridae family, close to SARS-CoV and MERS-CoV, which evolved globally with a death rate of 10% and 36% in 2002 and 2012 respectively¹. Usually, virus mutation is very fast and it was confirmed within a month that corona virus-2 was able to mutate rapidly. The genome and mutation rate over time is similar to SARS-CoV. The treatment approach for coronavirus is based on either

the disruption of coronavirus or increasing resistance in human cell². It can be achieved by measuring the antiviral efficacy of a wide variety of anti-viral drugs, interferon, and inhibitors such as cyclophilin used in the treatment of virus-induced pneumonia³, high-throughput screening of many therapeutic molecules⁴, design and characterization of valid vaccine or drug are quite essential⁵. Interferon plays a prime role in preventing viral replication by blocking the viral binding and replicating pathways of signals⁶. The SARS-CoV-2 spike protein can recognize the entry receptor for human angiotensin-converting enzyme II (ACE2) and infect the lung epithelial cells^{7,8}. The spike protein receptor-binding domain binds to the ACE2 receptor. The host protease TMPRSS2 breaks the spike protein to expose fusion peptides and they are capable of merging the viral membrane and cell membranes⁹. The susceptibility of host cells to being infected dictates the cellular tropism of the virus which is determined in

*Author for correspondence

SARS-CoV-2 by the presence of the receptor necessary for the entry of the ACE2 receptor. In many human tissues ACE2 is expressed, with different symptoms arising from infection^{10,11}. When a human cell is infected by SARS-CoV-2, the virion releases its RNA in the cytoplasm. Translation and replication occur and by exocytosis, new virions are then released from the cell¹².

2. Medicinal Plants

India is bestowed with rich biodiversity of fauna and flora. Usage of plant materials for prevention, management and treatment of various illness is common in Indian system of medicines like *Ayurveda*, *Siddha*, and *Unani*. The medicinal uses of plants have been documented in ancient *Vedas* and other scriptures. Later, *Ayurveda* developed between 2500 and 500 BC¹³. In Indian continent, plant products play a key role as pioneer sources of drugs¹⁴. India is very unique for its practice of traditional medicine and ethnomedicine. The traditional Indian medicinal formulations are multi-component blends whose therapeutic application is purely based on the scientific clinical evidence¹⁵. Medicinal plants have always played a pivotal role to overcome viral transmission causing diseases¹⁶. COVID-19 has made us realize the importance of herbal products in disease prevention. Ministry of AYUSH, Government of India has recommended many herbal based formulations as prevention or as control measures for COVID-19. The role of commonly used medicinal plants in India and other countries in the management of COVID-19 disease are reviewed in this paper.

3. *Andrographis paniculata*

Andrographis paniculata belongs to the family Acanthaceae and native to India and Sri Lanka. Commonly it is used in the treatment of influenza, diabetes, high blood pressure and skin diseases. It was reported in a study that more than 10 flavonoids and 20 diterpenoids were derived from *A. paniculata* which proved to have potent medicinal properties¹⁷. The chemical constituents were found to be in higher quantities in the plant leaves in comparison to other plant parts. It was noted that andrographolide and its derivatives from *A. paniculata* have strong antiviral activity against different classes of viruses, such as influenza virus, hepatitis B virus, herpes simplex virus, human immunodeficiency virus, human papilloma virus, etc. The Biomolecular docking, dynamics molecular and quantum mechanics based free energy calculations with selective molecules of AGP1, AGP2, AGP3, AGP4 were characterized against target macromolecules of 3CLpro, PLpro, RdRp with spike protein of corona virus. Few commercial drugs were compared with the selected

phytochemicals against the virus. It was found that AGP3 in future can be used as a promising drug for the COVID-19 treatment¹⁸. Many chemical constituents from *Curcuma longa* and *Andrographis paniculata* were studied to control the COVID-19 virus by *insilco* analysis against the main protease enzyme of SARS CoV-2. The chemical components such as andrographolide, cyclocurcumin, curcumin and dihydroxy dimethoxy flavone were active against the virus¹⁹.

4. *Glycyrrhiza glabra*

Glycyrrhiza glabra belongs to Fabaceae family and is native to Mediterranean region, Southern Europe and Southwest Asian regions. It contains glycyrrhizic acid (GLR), which is mainly used to cure diseases of the liver, viral hepatitis and specific inflammation of the skin. GLR showed activities against viruses, including humans and animals infected with SARS. GLR is a non-hemolytic saponin that has both cytoplasmic and membrane effects; it is a potent immuno-active anti-inflammatory agent. GLR induces cholesterol-dependent disorganization of lipid rafts at the membrane level. GLR plays a major role in prevention of coronavirus to enter cells. The HMGB1 gene encodes the high mobility group protein 1 (HMG-1) and amphoterin, a protein found in humans. Intra cellular level GLR can trap the HMG-1 to block the warning functions of HMGB1. Both the cholesterol and HMG boxbinding functions of GLR were studied and the molecular docking approach was carried out. In addition to its use as a safe medication, the membrane and cytoplasmic effects of GLR make GLR a promising candidate to be tested against COVID-19 infection in combination with other medications²⁰. In another *invitro* study SARS-related coronaviruses, respiratory syncytial viruses, arboviruses, vaccinia viruses, and vesicular stomatitis viruses were studied knowing the antiviral activity against HIV-1 virus. The mechanism for antiviral activity of *Glycyrrhiza spp.* include decreased transport to membrane and sialylation of the surface antigen of the hepatitis B virus, decreased membrane fluidity leading to inhibition of HIV-1 viral membrane fusion with the cell, interferon-gamma induction in T-cells, and phosphorylating enzyme inhibition in vesicular stomatitis virus infection and viral rate reduction²¹.

5. *Panax ginseng*

Panax ginseng belongs to the Araliaceae family and native to Korea. It is used to treat diabetes, cardiovascular diseases, central nervous system, and also act as an antioxidant. It was reported that ginsenosides, polysaccharides, polyacetylenes, phytosterols, and essential oils are the

active substances found in ginseng, where ginsenosides were known to be the main bioactive ingredient²²; it includes ginseng polysaccharides or ginseng saponin. The antiviral properties of ginseng polysaccharide and ginseng saponin have been studied and were found to be effective against influenza virus infection symptoms²³. In addition to antiviral activity, ginseng also has a role in viral infection as a mucosal adjuvant against the influenza virus²⁴.

6. *Withania somnifera*

Withania somnifera (Indian ginseng) is an antiviral, anti-inflammatory, and potent antioxidant plant. Using docking experiments, the protein targets of SARS-CoV-2, namely NSP15 endoribonuclease and the spike protein receptor binding domain were targeted. The findings showed that at the binding site of selected proteins the glucoside compounds withanoside X and quercetin from *W. somnifera* has favorable interactions. Withanoside X was found to be the most promising inhibitor with the highest binding free energy ($G_{\text{bind}} = -89.42$ kcal/mol). The molecule optimizes its conformation during MD studies to better fit with the receptor active site, explaining the high binding affinity. Indian ginseng may also be used as one of the alternatives for the treatment of the COVID-19 virus based on proven therapeutic evidence²⁵.

7. *Azadirachta indica*

Azadirachta indica belongs to the Meliaceae family and is native to the Indian subcontinent. Its uses are multifarious and has been used as a medicinal herb since ancient times. Neem leaves exhibit anti-microbial, anti-inflammatory, and also anti-viral properties. To identify coronavirus membrane and envelope protein inhibitors, molecular docking and simulation methods were used. These proteins were virtually screened against a total of 70 neem plant compounds and further examined for the identification of some potential compounds. These compounds bound themselves to the proteins of the virus, proving their capability to suppress the functionality of these components. Identification of inhibitors can be further studied against COVID-19 infection using computational techniques²⁶.

8. *Carissa spinarum*

Carissa spinarum or bush plum is a shrub belonging to the Apocynaceae family and native to tropical regions of Africa, Southern Asia, and Australia. It is used for inflammation, arthritis, epilepsy, viral infection, and cancer treatment. *Carissa spinarum* is used for its anti-

viral properties due to the presence of alkaloids, tannin, glycosides, saponins, terpenoids, flavonoids, and steroids. The chemical constituents include primary and secondary metabolites which play a key role in the defense mechanism against injury and viral diseases²⁷. These are found in the leaves, fruits, stems, bark, seeds, and roots.

9. *Curcuma longa*

Curcuma longa is a herb rich in curcumin belonging to the family Zingiberaceae and native to tropical South Asia. It has antiviral, anti-inflammatory, antipyretic, antifatigue, and other properties that could be very effective against COVID-19. In a study, curcumin was found to interfere with SARS-CoV-2 viral replication mechanisms and to be effective in the therapeutic intervention of COVID-19 infection²⁸. Curcumin has been proven to inhibit SARS-corona virus replication²⁹. The genomic similarity of SARS-CoV-2 with SARS-coronavirus (>80%) and Middle East respiratory syndrome-coronavirus indicates the possibility of curcumin being used as a potent compound against COVID-19³⁰.

10. *Nigella sativa*

Nigella sativa belongs to the family Ranunculaceae and is native to Eastern Europe and Western Asia. The herb is used to treat various illnesses, including influenza, headache, high blood pressure, diabetes, inflammation, eczema, fever, and asthma. Computational analysis of molecular docking, ADMET and MM-PBSA has been used to characterize the *N. sativa* therapeutic potential against COVID-19. Dithymoquinone (DTQ) a compound in *N. sativa* along with ACE2 interface showed a high affinity for SARS-CoV-2 and interacts with several hotspot residues both by hydrophobic and hydrophilic bonding. This compound has high solubility, absorption rates, and is found to be a promising biomolecule against infection³¹. It was also noticed that *N. sativa* includes other bioactive components such as thymoquinone, nigellimine, dithymoquinone, and thymohydroquinone. *N. sativa* can be used along with a Zinc supplement³². In general, for any infection, Zn enhances the immunity. The added Zn salt supplement with *N. sativa* acts as an ionophore to allow Zn²⁺ to enter pneumocytes the target cell for SARS-CoV-2. Zn salts are known to inhibit the replication of viruses such as HIV, HSV, and SARS-CoV. In these viruses, Zn is known to impede the viral entry or inhibiting the viral RdRp activity³³⁻³⁵.

11. Other Folk Herbal Medicines

It was reported that some essential oils, including *Cinnamomum zeylanicum* leaf oil, *Citrus bergamia*, *Cymbopogon flexuosus* and *Thymus vulgaris*³⁶, also exhibit anti-influenza properties. *Laurus nobilis* has been used as a folk medicine to treat diseases caused by SARS-CoV³⁷. *Juniperus oxycedrus* plant are used in folk medicine for the treatment of various infectious diseases³⁸. *Aloysiagratisissima* and *Artemisia arborescens* exhibit antiviral activity against HSV-1 and HSV-2 virus^{39,40}. *Leptospermum scoparium*, *Matricaria recutita*, *Melaleuca alternifolia*, and *Mentha piperita* exhibit antiviral properties against HSV-1/HSV-2 virus⁴¹⁻⁴⁴. Antiviral compounds such as Curcumin, Oleuropein, Luteolin-7, and Catechin from plants like *Capsicum annuum*, *Curcuma longa*, *Mentha longifolia*, *Olea europaea*, *Phoenix hanceana*, and *Camellia sinensis* was found to inhibit Mpro coronavirus⁴⁵. Tylophorine compounds from the *Tylophora indica* exhibit potentials inhibiting coronaviruses⁴⁶.

Psoralea corylifolia contains antiviral compounds such as Bavachinin, Psoralidin Corylifol; they were studied against SARS-CoV and ethanol extract of secondary metabolites recorded high activity against SARS-CoV PLpro⁴⁷. *Paulownia tomentosa* containing tomentin compound was used for treating SARS-CoV infection⁴⁸. *Camellia sinensis* containing catechins was also used as inhibitors of SARS-CoV N protein⁴⁹.

Myricetin and Scutellare in compounds present in *Aglaia perviridis* were used for the treatment of SARS-CoV. *In vitro* study affects the ATPase activity which inhibits the SARS-CoV helicase protein⁵⁰. The use of *Kadha* (herbal tea/decoction) a mixture of *Ocimum tenuiflorum*, *Cinnamomum verum*, *Piper nigrum*, *Zingiber officinale*, and *Vitis vinifera* was given to boost immunity against coronavirus⁵¹. *Zingiber officinale* also contains the quercetin flavonoid, which has shown *in silico* potential to bind to the main protease (3CLpro) of SARS-CoV and SARS-CoV-2⁵². Digitoxigenin in *Nerium oleander* was used in treatment as antiviral and anti-cancer inhibitors⁵³. *W. somnifera*, *T. cordifolia*, and *O. sanctum* phytoconstituents not only impede the interaction of viral protein to the host cell but also serve safe against coronavirus without exhibiting any toxicity⁵⁴.

Various diseases like asthma, sinuses, fever, and chronic indigestion can be cured with the help of *Piper nigrum* fruit. Antiviral activity against vesicular stomatitis Indiana virus and Human parainfluenza virus has been exhibited by the chloroform seeds extract^{55,56}. Antiviral activity against Cocksackievirus was demonstrated by piperamides found in the plant⁵⁷. The leaf extract of

Vitex negundo was found to inhibit the Chikungunya virus⁵⁸. It was reported that *Phaseolus Vulgaris* plant was confirmed to have antiviral property against the human immunodeficiency virus-1 and Drosophila C virus⁵⁹⁻⁶¹.

Calendula flavonoid based chemical constitutes such as rutin, isorhamnetin-3-O-b-D, and calendoflaside were selected and found to be highly effective in inhibiting Mpro, the main protease for SARS-CoV-2 causing COVID-19. They have the ability to form a stable complex with Mpro, these three molecules from *Calendula officinalis*, especially calendoflaside and rutin compounds, proved to be an anti-COVID-19 protease drug to fight against the novel protease drug but however it requires clinical trials for further analysis⁶².

Asparagus racemosus was studied using molecular docking and dynamic approaches against SARS-CoV-2. Two proteins NSP15 endoribonuclease and spike receptor-binding domain of SARS-CoV-2 along with the plant compounds were examined. The compounds Asparoside-C, Asparoside-D, and Asparoside-F were found to be more effective molecules with NSP15 and complex molecule domain of receptor binding site of SARS-CoV-2 with the reference of molecular docking and dynamic studies. The molecular interaction has also theoretically proved that MM-GBSA has moderate molecular affinity and better interaction with Asparoside-C and Asparoside-F against virus spike protein binding domain along with Endoribonuclease respectively. *Asparagus racemosus* has antiviral potential and it showed that Asparoside-C and Asparoside-F have a good binding with target proteins and serve as an inhibitor⁶³.

Metabolites found in conifer angiosperm families are Abietane-type diterpenes, more than 200 compounds exhibited anti-inflammatory, anti-diabetic, antitumor, antimicrobial, and antimalarial properties. It was found that both betunolic acid and savinin compounds are present in Cupressaceae species. Lignoid groups with antiviral activity have been tested recently. In addition to their diversity of bioactive compounds, dibenzylbutyrolactones primarily exhibit antiviral activity. Savinin and hinokinin compounds are active against SARS-CoV-1 and HIV^{64,65}.

12. Discussion

The research implication on COVID-19 alone in 21st century contributed more than 60% to the publication history. New drug research against the virus is constantly being carried out to solve human problems using different biological and synthetic method. Most of the pharmaceutical companies in the world are designing inactivated or attenuated rapid vaccines for COVID-19,

however very few have been successful with different efficacy rates. Though the inactivated and attenuated vaccines may provide effective immune response, existing problem like reversion of virulence and other side effects associated with this vaccine developing strategy yet to be studied carefully. Indeed, the post immunization research on humans could result in either a positive or negative impact. Meanwhile these kinds of rapid vaccines are assumed to be having some genetic side effects. Because of these reasons few countries are hesitating to take the rapid vaccines. Hence, the responsibility of pharmaceutical companies is to design a suitable synthetic drug or natural derivative to eradicate the viral infection without side effects. During the initial period of COVID-19 viral infection, many South East Asian countries used several traditional antiviral herbal extracts to improve the health status of infected people and prevent the infection in healthy people. Indeed, these traditional plant extracts were shown to provide more than 90% recovery from the infection in many patients.

A variety of chemical constituents from plant origins including Myricitrin, Licoleafol, Curcumin, and Crocin, have been suggested as possible inhibitors for COVID-19 based on *insilico* approach. *In vitro* phytoconstituent evaluation studies have shown that diammonium glycyrrhizinate, chloroquine diphosphate, and hydroxychloroquine can be potential COVID-19 virus inhibitors, and few of them are in clinical trials. Plants like *Alnus japonica*, *Angelica keiskei*, *Cibotium barometz*, *Cullen corylifolium*, *Ecklonia cava*, *Paulownia tomentosa*, *Quercus infectoria*, *Rheum* sp., *Polygonum* sp., *Salvia multiorrhiza*, *Sambucus javanica*, *Scutellaria baicalensis*, *Torreya nucifera* and *Tribulus terrestris* were also evaluated for *in-vitro* and shown effective inhibition of COVID-19.

Information obtained from literature studies show that the promising treatment for COVID-19 may be from the use of conventional medicinal extracts alone or in combination with synthetic drugs. Using the traditional medicine strategy, one has to determine their bioactivity, inhibition properties, biological evaluation, and further investigation about the potentials of many plant-based phytochemicals against the COVID-19 infection.

13. Conclusion

The recent global problem is the COVID-19 pandemic. There is a wide scope for medicinal plants which possess antiviral properties to be developed into anti-COVID-19 drugs. The best way of preventing COVID-19 infections would be to identify the right type of compound from the right type of medicinal plant, responsible for altering

or disturbing any steps of the virus replication cycle. It is important to explore herbal products capable of inhibiting or altering the structural protein (spike glycoprotein) configuration, non-structural proteins (3-chymotrypsin-like protease, papain-like protease, helicase, and RdRp), and accessory proteins coded by the SARS-CoV-2 genome. It is always safe to use herbal products which are proved to be very secure, safe, and an efficient source for drug detection responsible for managing the current pandemic situation.

There is a dire need to investigate Protease and RNA polymerase inhibitors known to be active against SARS and MERS. Different phytochemicals (flavonoids, polyphenols, alkaloids, proanthocyanidins, and terpenoids) have already been proved to have antiviral properties; they need to be screened while treating SARS-CoV-2 infected patients. There is a wide scope for herbal extracts in Indian continent which may help relieve the symptoms and be effective against COVID-19 infection without any side effects but with more therapeutic efficacy.

14. Abbreviation

ACE2-Angiotensin-Converting Enzyme 2

ADMET-Absorption, Distribution, Metabolism, Excretion and Toxicology

ARDS-Acute Respiratory Distress Syndrome

COVID-19- Corona Virus Disease-19

DTQ- Dithymoquinone

GLR- Glycyrrhizic Acid

HIV-Human Immunodeficiency Virus

HMG-1 -High Mobility Group Protein-1

HSV-Herpes Simplex Virus

MD- Molecular Docking

MERS-Middle East Respiratory Syndrome

MM-PBSA-Molecular Mechanics Poisson-Boltzmann Surface Area

RdRp-RNA-directed RNA polymerase

RNA- Ribonucleic acid

SARS-Severe Acute Respiratory Syndrome

SARS-CoV-2-Severe Acute Respiratory Syndrome Coronavirus-2

TMPRSS2- Transmembrane serine protease 2

Zn-Zinc

15. References

1. Reusken CB, Haagmans BL, Müller MA, Gutierrez C, Godeke G-J, Meyer B, *et al.* Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. *Lancet Infect Dis.* 2013; 13(10):859–66. [https://doi.org/10.1016/S1473-3099\(13\)70164-6](https://doi.org/10.1016/S1473-3099(13)70164-6)
2. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, *et al.* Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. *Lancet Infect Dis.* 2014; 14(11):1090–5. [https://doi.org/10.1016/S1473-3099\(14\)70920-X](https://doi.org/10.1016/S1473-3099(14)70920-X)
3. Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. *J Biomol Struct Dyn.* 2020. p.1–6. <https://doi.org/10.1080/07391102.2020.1752802>. PMID:32248766
4. Chan JFW, Chan K-H, Kao RYT, To KKW, Zheng B-J, Li CPY, *et al.* Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. *J Infect.* 2013; 67(6):606–16. <https://doi.org/10.1016/j.jinf.2013.09.029>. PMID: 24096239. PMID:32248766
5. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, *et al.* Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture. *Antimicrob Agents Chemother.* 2014; 58(8):4875–84. <https://doi.org/10.1128/AAC.03011-14>. PMID:24841269 PMID:32248766
6. Dyal J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, *et al.* Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. *Antimicrob Agents Chemother.* 2014; 58(8):4885–93. <https://doi.org/10.1128/AAC.03036-14>. PMID:24841273 PMID:32248766
7. Velavan TP, Meyer CG. The COVID-19 epidemic. *Trop Med Int Health.* 2020; 25(3):278–80. <https://doi.org/10.1111/tmi.13383>. PMID:32052514 PMID:32248766
8. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. *Intensive Care Med.* 2020; 46(4):586–90. <https://doi.org/10.1007/s00134-020-05985-9>. PMID:32125455 PMID:32248766
9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, *et al.* SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020; 181(2):271–80. <https://doi.org/10.1016/j.cell.2020.02.052>. PMID:32142651 PMID:32248766
10. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol.* 2004; 203(2):631–7. <https://doi.org/10.1002/path.1570>. PMID:15141377 PMID:32248766
11. Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infect Dis Poverty.* 2020; 9(1). <https://doi.org/10.1186/s40249-020-00662-x>. PMID:32345362 PMID:32248766
12. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *J Med Virol.* 2020; 92(4):418–23. <https://doi.org/10.1002/jmv.25681>. PMID: 31967327. PMID:32248766
13. Subhose V, Srinivas P, Narayana A. Basic principles of pharmaceutical science in Ayurveda. *Bull Indian Inst Hist Med Hyderabad.* 2005; 35(2):83–92.
14. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. *Nat Rev Drug Discov.* 2005; 4(3):206–20. <https://doi.org/10.1038/nrd1657>. PMID:15729362
15. Pandey MM, Rastogi S, Rawat AKS. Indian traditional ayurvedic system of medicine and nutritional supplementation. *Evid Based Complement Alternat Med.* 2013; 2013. <https://doi.org/10.1155/2013/376327>. PMID:23864888 PMID:32248766
16. Balachandar V, Mahalaxmi I, Kaavya J, Vivekanandhan G, Ajithkumar S, Arul N, *et al.* COVID-19: emerging protective measures. *Eur Rev Med Pharmacol Sci.* 2020; 24(6):3422–5.
17. Thisoda P, *et al.* Inhibitory Effect of andrographis paniculata extract and its active diterpenoids on platelet aggregation. *Eur J Pharmacol.* 2006; 553(1–3):39–45. <https://doi.org/10.1016/j.ejphar.2006.09.052>. PMID:17081514
18. Murugan NA, Pandian CJ, Jeyakanthan J. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known

- antiviral compounds in drug trials. *J Biomol Struct Dyn.* 2020; 16:1-12. <https://doi.org/10.1080/07391102.2020.1777901>. PMID:PMC7309306
19. Rajagopal K, Varakumar P, Baliwada A, Byran G. Activity of phytochemical constituents of *Curcuma longa* (turmeric) and *Andrographis paniculata* against coronavirus (COVID-19): An in silico approach. *Future J Pharm Sci.* 2020; 6(1). <https://doi.org/10.1186/s43094-020-00126-x>. PMID:33215042. PMID:PMC7562761
20. Bailly C, Vergoten G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? *Pharmacol Ther.* 2020; 214(107618). <https://doi.org/10.1016/j.pharmthera.2020.107618>. PMID:32592716. PMID:PMC7311916
21. Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, et al. Antiviral effects of Glycyrrhiza species. *Phytother Res.* 2008; 22(2):141–8. <https://doi.org/10.1002/ptr.2295>. PMID: 17886224. PMID:PMC7167979
22. Park JD, Rhee DK, Lee YH. Biological activities and chemistry of Saponins from *Panax ginseng* C. A. Meyer. *Phytochem Rev.* 2005; 4(2-3):159–75. <https://doi.org/10.1007/s11101-005-2835-8>
23. Yin SY, Kim HJ, Kim H-J. A comparative study of the effects of whole red ginseng extract and polysaccharide and saponin fractions on Influenza A (H1N1) virus infection. *Biol Pharm Bull.* 2013; 36(6):1002–7. <https://doi.org/10.1248/bpb.b13-00123>. PMID:23727921
24. Quan FS, Compans RW, Cho Y-K, Kang S-M. Ginseng and *Salviae* herbs play a role as immune activators and modulate immune responses during influenza virus infection. *Vaccine.* 2007; 25(2):272–82. <https://doi.org/10.1016/j.vaccine.2006.07.041>. PMID:16945454
25. Chikhale RV, Gurav SS, Patil RB, Sinha SK, Prasad SK, Shakya A, et al. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach. *J Biomol Struct Dyn.* 2020; 1–12. <https://doi.org/10.1080/07391102.2020.1778539>. PMID:PMC7332873
26. Borkotoky S, Banerjee M. A computational prediction of SARS-CoV-2 structural protein inhibitors from *Azadirachta indica* (Neem). *J Biomol Struct Dyn.* 2020; 1–11. <https://doi.org/10.1080/07391102.2020.1774419>. PMID: 32462988. PMID:PMC7311162
27. Ansari I, Patil DT. A brief review on phytochemical and pharmacological profile of *Carissa spinarum* L. *Asian J Pharm Clin Res.* 2018; 11(9):12. <https://doi.org/10.22159/ajpcr.2018.v11i9.26316>
28. Babaei F, Nassiri-Asl M, Hosseinzadeh H. Curcumin (a constituent of turmeric): New treatment option against COVID-19. *Food Sci Nutr.* 2020; 8(10):5215–27. <https://doi.org/10.1002/fsn3.1858>. PMID: 33133525. PMID:PMC7590269
29. Wenz C-C, Kuo Y-H, Jan J-T, Liang P-H, Wang S-Y, Liu H-G, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. *J Med Chem.* 2007 Aug; 50(17):4087–95. <https://doi.org/10.1021/jm070295s>. PMID:17663539
30. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet.* 2020; 395(10224):565–74. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
31. Ahmad S, Abbasi HW, Shahid S, Gul S, Abbasi SW. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: A computational quest to identify potential natural antiviral for COVID-19 treatment. *J Biomol Struct Dyn.* 2020; 1–9. <https://doi.org/10.1080/07391102.2020.1775129>. PMID:PMC7298883
32. Haraguchi Y, Sakurai H, Hussain S, Anner BM, Hoshino H. Inhibition of HIV-1 infection by zinc group metal compounds. *Antiviral Res.* 1999; 43(2):123–33. [https://doi.org/10.1016/S0166-3542\(99\)00040-6](https://doi.org/10.1016/S0166-3542(99)00040-6)
33. Katz E, Margalith E. Inhibition of vaccinia virus maturation by zinc chloride. *Antimicrob. Agents Chemother.* 1981; 19(2):213–7. <https://doi.org/10.1128/AAC.19.2.213>. PMID:7347557. PMID:PMC181396
34. Kaushik N, Subramani C, Anang S, Muthumohan R, Shalimar, Nayak B, et al. Zinc salts block Hepatitis E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase. *Ou J-H J, ed. J. Virol.* 2017; 91(21). <https://doi.org/10.1128/JVI.00754-17>. PMID:28814517. PMID:PMC5640865
35. te Velhuis, Aartjan te Velhuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn²⁺ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *Andino R, ed. PLoS Pathogens.* 2010; 6(11). <https://doi.org/10.1371/journal.ppat.1001176>. PMID:21079686. PMID:PMC2973827
36. Vimalanathan S, Hudson J. Anti-influenza virus activity of essential oils and vapors. *Amer J Essential Oil Nat Prod.* 2014; 2(1).
37. Loizzo MR, Saab AM, Tundis R, Statti GA, Menichini F, Lampronti I, et al. Phytochemical analysis and in

- vitro antiviral activities of the essential oils of seven Lebanon species. *Chem Biodivers.* 2008; 5(3):461–70. <https://doi.org/10.1002/cbdv.200890045>. PMID:18357554. PMCID:PMC7161995
38. Reichling J, Schnitzler P, Suschke U, Saller R. Essential oils of aromatic plants with antibacterial, antifungal, antiviral, and cytotoxic properties - An overview. *Complement Med Res.* 2009; 16(2):79–90. <https://doi.org/10.1159/000207196>. PMID:19420953
39. García CC, Talarico L, Almeida N, Colombres S, Duschatzky C, Damonte EB. Virucidal activity of essential oils from aromatic plants of San Luis, Argentina: Virucidal activity of essential oils. *Phyther Res.* 2003; 17(9):1073–5. <https://doi.org/10.1002/ptr.1305>. PMID:14595590
40. Saddi M, Sanna A, Cottiglia F, Chisu L, Casu L, Bonsignore L, *et al.* Antitherpevirus activity of *Artemisia arborescens* essential oil and inhibition of lateral diffusion in Vero cells. *Ann Clin Microbiol Antimicrob.* 2007; 6(1):10. <https://doi.org/10.1186/1476-0711-6-10>. PMID:17894898. PMCID:PMC2099429
41. Reichling J, Koch C, Stahl-Biskup E, Sojka C, Schnitzler P. Virucidal activity of a β -Triketone-rich essential oil of *Leptospermum scoparium* (Manuka Oil) against HSV-1 and HSV-2 in cell culture. *Planta Medica.* 2005 Nov; 71(12):1123–7. <https://doi.org/10.1055/s-2005-873175>. PMID:16395648
42. Schnitzler P, Reichling J. Efficacy of plant products against herpetic infections. *HNO.* 2011; 59(12):1176–84. <https://doi.org/10.1007/s00106-010-2253-0>. PMID:21607799. PMCID:PMC7080060
43. Koch C, Reichling J, Schnitzler P: Essential oils inhibit the replication of herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2); in Preedy VR, Watson RR (eds): *Botanical Medicine in Clinical Practice*. Wallingsford, CABI; 2008. p. 192–7. <https://doi.org/10.1079/9781845934132.0192>. PMID:18093145
44. Schnitzler P, Schön K, Reichling J. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. *Pharmazie.* 2001; 56(4):343–7.
45. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Preprints. <https://doi.org/10.20944/preprints202003.0226.v1>. PMID:32934811. PMCID:PMC7469571
46. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new Coronavirus (SARS-CoV-2): A review and perspective. *Int J Biol Sci.* 2020; 16(10):1708–17. <https://doi.org/10.7150/ijbs.45538>. PMID:32226288. PMCID:PMC7098036
47. Kim DW, Seo KH, Curtis-Long MJ, Oh KY, Oh J-W, Cho JK, *et al.* Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of *Psoralea corylifolia*. *J Enzyme Inhib Med Chem.* 2014; 29(1):59–63. <https://doi.org/10.3109/14756366.2012.753591>. PMID:23323951
48. Cho JK, Curtis-Long MJ, Lee KH, Kim DW, Ryu HW, Yuk HJ, *et al.* Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of *Paulownia tomentosa*. *Bioorg Med Chem.* 2013; 21(11):3051–7. <https://doi.org/10.1016/j.bmc.2013.03.027>. PMID:23623680. PMCID:PMC7126831
49. Roh C. A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide. *Int J Nanomedicine.* 2012; 7:2173–9. <https://doi.org/10.2147/IJN.S31379>. PMID:22619553. PMCID:PMC3356205
50. Yu M-S, Lee J, Lee JM, Kim Y, Chin Y-W, Jee J-G, *et al.* Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. *Bioorg Med Chem Lett.* 2012; 22(12):4049–54. <https://doi.org/10.1016/j.bmcl.2012.04.081>. PMID:22578462. PMCID:PMC7127438
51. Khanal P, Duyu T, Patil BM, Dey YN, Pasha I, Wanjari M, *et al.* Network pharmacology of AYUSH recommended immune-boosting medicinal plants against COVID-19. *J Ayurveda Integr Med [Internet].* 2020. Available from: <http://dx.doi.org/10.1016/j.jaim.2020.11.004>. PMID:33250601. PMCID:PMC7687402
52. Aanouz I, Belhassan A, El-Khatabi K, Lakhlifi T, El-Ildrissi M, Bouachrine M. Moroccan medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations. *J Biomol Struct Dyn.* 2020; 1–9. <https://doi.org/10.1080/07391102.2020.1758790>. PMID:32306860. PMCID:PMC7212546
53. Reddy D, Kumavath R, Barh D, Azevedo V, Ghosh P. Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions. *Molecules.* 2020; 25(16). <https://doi.org/10.3390/molecules25163596>. PMID:32784680. PMCID:PMC7465415
54. Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, *et al.* Targeting COVID-19 (SARS-CoV-2)

- main protease through active phytochemicals of ayurvedic medicinal plants - *Withania somnifera* (Ashwagandha), *Tinospora cordifolia* (Giloy) and *Ocimum sanctum* (Tulsi) - A molecular docking study. *J Biomol Struct Dyn.* 2020; 1–14. <https://doi.org/10.1080/07391102.2020.1810778>. PMID:32851919. PMCid:PMC7484581
55. Priya NC, Kumari PS. Antiviral activities and cytotoxicity assay of seed extracts of *Piper longum* and *Piper nigrum* on human cell lines. *Int J Pharm Sci Rev Res.* 2017; 44(1):197–202.
56. Priya NC, Kumari PS. Antiviral activities and cytotoxicity assay of seed extracts of *Piper longum* and *Piper nigrum* on human cell lines. *Int J Pharm Sci Rev Res.* 2017; 44(1):197–202.
57. Mair CE, Liu R, Atanasov AG, Schmidtke M, Dirsch VM, Rollinger JM. Antiviral and anti-proliferative in vitro activities of piperamides from black pepper. *Planta Med.* 2016; 81(S 01):S1–381. <https://doi.org/10.1055/s-0036-1596830>
58. Bhakat S, Soliman MES. Chikungunya virus (CHIKV) inhibitors from natural sources: A medicinal chemistry perspective. *J Nat Med.* 2015 Apr 29; 69(4):451–62. <https://doi.org/10.1007/s11418-015-0910-z>. PMID:25921858. PMCid:PMC4703636
59. Ekowati H, Arai J, Damana Putri AS, Nainu F, Shiratsuchi A, Nakanishi Y. Protective effects of *Phaseolus vulgaris* lectin against viral infection in *Drosophila*. *Drug Discov Ther.* 2017; 11(6):329–35. <https://doi.org/10.5582/ddt.2017.01071>. PMID:29332891
60. Kumar RV. Plant antiviral immunity against geminiviruses and viral counter-defense for survival. *Front Microbiol.* 2019; 10:1460. <https://doi.org/10.3389/fmicb.2019.01460>. PMID:31297106. PMCid:PMC6607972
61. Ye XY, Ng TB, Tsang PW, Wang J. Isolation of a homodimeric lectin with antifungal and antiviral activities from red kidney bean (*Phaseolus vulgaris*) seeds. *J Protein Chem.* 2001; 20:367–75. <https://doi.org/10.1023/A:1012276619686>. PMID:11732688
62. Das P, Majumder R, Mandal M, Basak P. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (Mpro) from flavonoid based phytochemical constituents of *Calendula officinalis*. *J Biomol Struct Dyn.* 2020 Jul 24; 1–16. <https://doi.org/10.1080/07391102.2020.1796799>. PMCid:PMC7441784
63. Chikhale RV, Sinha SK, Patil RB, Prasad SK, Shakya A, Gurav N, et al. In-silico investigation of phytochemicals from *Asparagus racemosus* as plausible antiviral agent in COVID-19. *J Biomol Struct Dyn.* 2020 Jun 24; 1–15. <https://doi.org/10.1080/07391102.2020.1784289>. PMCid:PMC7335809
64. Wen C-C, Kuo Y-H, Jan J-T, Liang P-H, Wang S-Y, Liu H-G, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. *J Med Chem.* 2007; 50(17):4087–95. <https://doi.org/10.1021/jm070295s>. PMID:17663539
65. Cui Q, Du R, Liu M, Rong L. Lignans and their derivatives from plants as antivirals. *Molecules.* 2020; 25(1):183. <https://doi.org/10.3390/molecules25010183>. PMID:31906391. PMCid:PMC6982783